257K shares changed hands in the last trading session. Overall, volume was up 253.17% over the stocks normal daily volume. Traders are a little more bullish of late as shown by the downtick in short interest. The company recorded a fall in short interest between June 15, 2017 and May 31, 2017 of -45.00%. Short interest decreased from 280,851 to 154,478 over that timeframe.
Here are some other firms who have updated their holdings. Morgan Stanley bolstered its stake by buying 1,778 shares an increase of 56.7%. Morgan Stanley controls 4,913 shares with a value of $196,000. The total value of its holdings increased 133.3%. Price T Rowe Associates Inc /md/ divested its holdings by shedding 86,994 shares a decrease of 3.6% as of 03/31/2017. Price T Rowe Associates Inc /md/ now holds 2,332,347 shares valued at $92,967,000. The value of the position overall is up by 43.6%.
As of quarter end Baker Bros. Advisors Lp had bought 54,569 shares growing its stake by 2.5%. The value of the company’s investment in Advanced Accelerator Applicatio went from $57,993,000 to $88,557,000 a change of 52.7% quarter over quarter. Scopia Capital Management Lp downsized its ownership by selling 551,340 shares a decrease of 30.9% from 12/31/2016 to 03/31/2017. Scopia Capital Management Lp owns 1,231,442 shares worth $49,085,000. The value of the position overall is up by 2.9%.
Equity analyst JP Morgan starting coverage on AAAP with a rating of “Overweight”. On November 29 the stock rating was downgraded to “Market Perform” from “Outperform” in an announcement from Wells Fargo.
Wells Fargo began coverage with an initial rating of “Outperform”. March 16 investment analysts at Citigroup made no change to the stock rating of “Neutral” but raised the price expectation to $36.00 from $32.00.
On March 9 JMP Securities left the stock rating at “Market Outperform” and lowered the price target from $44.00 to $36.00. On December 7 analysts at Canaccord Genuity initiated coverage giving it an initial rating of “Buy”.
The company is now up from yesterday’s close of $39.69.
Advanced Accelerator Applications S.A., launched on March 1, 2002, is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. AAA’s diagnostic product is Gluscan, its branded 18-fluorodeoxyglucose (FDG) PET imaging agent. Gluscan assists in the diagnosis of serious medical conditions, primarily in oncology, by assessing glucose metabolism. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications..